Recently, Galaxy Brain Scientific’s independently developed brain circuit pacemaker—the world’s first device based on personalized Brain Function Sectors (pBFS) technology—was officially installed at China’s first “Clinical and Translational Ward for Brain-Computer Interfaces” at Beijing Tiantan Hospital, Capital Medical University. It has become one of the ward’s first core therapeutic devices.

As the national flagship institution for neurological disease diagnosis and treatment in China, Beijing Tiantan Hospital’s establishment of the country’s first “Clinical and Translational Ward for Brain-Computer Interfaces” represents the highest platform for clinical research in brain-computer interfaces domestically. The ward fosters a unique collaborative innovation system integrating “medicine, engineering, research, industry, and policy,” aiming to accelerate the clinical translation of brain-computer interface technologies and provide patients with neurological disorders access to cutting-edge, systematic diagnostic and therapeutic pathways. The selection of Galaxy Brain Scientific’s brain circuit pacemaker as one of the ward’s first core devices fully demonstrates its comprehensive recognition by a national authoritative platform in terms of technological advancement, clinical value, and industrial translation capabilities.

The core competitiveness of the brain circuit pacemaker stems from its reliance on the globally leading brain science technology—personalized Brain Function Sectors (pBFS). This technology, pioneered by Professor Liu Hesheng, Chief Scientist at Changping Laboratory and a researcher at the Biomedical Pioneering Innovation Center of Peking University, is the world’s only individualized brain function subdivision technology that meets clinical needs. It can “read” an individual’s central neural signals, “decode” a unique functional map of each person’s brain, and develop personalized therapeutic target plans for patients, precisely selecting the most effective neural circuit targets.

Unlike invasive brain-computer interfaces that require craniotomy for implantation, the brain circuit pacemaker adopts a non-invasive approach to perform neuromodulation targeting individualized therapeutic sites, thereby treating brain dysfunction. This method avoids the risks and trauma associated with surgery while offering high precision and strong adaptability to individual patients, providing a safer and more effective treatment option. Currently, it has demonstrated significant clinical potential in a range of difficult-to-treat neurological disorders with limited traditional treatment options, such as Parkinson’s disease, post-stroke sequelae, and refractory depression. Not long ago, its cutting-edge technological strength earned it a place in the National High-End Medical Equipment Promotion and Application Project.

The installation of the brain circuit pacemaker at Tiantan Hospital marks not only a critical step forward in the clinical application of brain science research in China but also a significant reflection of the country’s independent innovation capabilities in the high-end medical equipment sector. As the brain circuit pacemaker undergoes deeper clinical application and validation in the future, it will open a new chapter in non-invasive brain-computer interface therapy. Meanwhile, leveraging the Tiantan Hospital platform, Galaxy Brain Scientific will further participate in promoting nationwide multicenter clinical research and the development of industry standards, helping China’s brain-computer interface industry secure a leading position in global competition.